Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

2014304 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 15, Issue 8, pp. 799-808

Field-Weighted Citation Impact: 65.87